Skip to Content

'
Michelle A.T. Hildebrandt, Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor (Tenure-Track), Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit Number: 1340
Houston, TX 77030
Room Number: CPB4.3281
Phone: 713 792-2242
Fax: 713 792-4657
Email: mhildebr@mdanderson.org

Education & Training

Degree-Granting Education

2007 Mayo Clinic College of Medicine, Rochester, MN, PHD, Molecular Pharmacology and Experimental Therapeutics, Mentor: Richard Weinshilboum, M.D.
2001 University of Wisconsin-River Falls, River Falls, WI, BS, Biology

Postgraduate Training

2007-2009 Research Fellowship, Cancer Prevention Research Training Program, Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, Mentor: Xifeng Wu, M.D., Ph.D.
2005 Short Course in Medical and Experimental Mammalian Genetics, The Jackson Laboratory, Bar Harbor, ME

Experience/Service

Academic Appointments

Assistant Professor (Research Faculty Appointment), Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2012-7/2013
Instructor, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2010-5/2012

Honors and Awards

2012 Highly Rated Poster Presentation, AACR Annual Meeting
2012 Leading Mentor in Cancer Prevention Award - Honorable Mention, MD Anderson Division of Cancer Prevention and Population Sciences
2009 American Association for Cancer Research Scholar-in-Training Award, funded by Susan G. Komen for the Cure, AACR - Frontiers in Cancer Prevention Research Meeting
2009 Bayer HealthCare Pharmaceuticals, Inc. Award for Postgraduate Population/Patient-Oriented Research, MD Anderson Cancer Center Trainee Research Day
2009 MD Anderson Trainee Excellence Award, MD Anderson Cancer Center
2009 Trainee of the Quarter Award, MD Anderson Cancer Center
2008 Bayer HealthCare Pharmaceuticals, Inc. Award for Postgraduate Population/Patient-Oriented Research and Winner of Poster Presentation Competition, MD Anderson Cancer Center Trainee Research Day
2007-2009 Cancer Prevention Training Program Fellowship, NCI/MD Anderson Cancer Center
2005 Mayo Graduate School Travel Award, Mayo Clinic College of Medicine
2005 Top Abstract, American Society of Clinical Pharmacology and Therapeutics Annual Meeting
2000 Summer Student Training Program, The Jackson Laboratory

Selected Publications

Peer-Reviewed Original Research Articles

1. Pu X, Hildebrandt MA (co-first author), Lu C, Roth JA, Stewart DJ, Zhao Y, Heist RS, Ye Y, Chang DW, Su L, Minna JD, Lippman SM, Spitz MR, Christiani DC, Wu X. Analysis of Variants in Inflammation Pathway as Predictors of Survival in Patients with Advanced Non-Small Cell Lung Cancer Receiving First Line Chemotherapy. Clin Pharmacol Ther. In Press.
2. Pu X, Wang L, Chang J, Hildebrandt MA, Ye Y, Lu C, Skinner H, Niu N, Jenkins G, Komaki R, Minna J, Roth J, Weinshilboum R, Wu X. Inflammation-related genetic variants predict toxicities following definitive-radiotherapy for lung cancer. Clin Pharmacol Ther. In Press.
3. Earp MA, Kelemen LE, Magliocco AM, Swenerton KD, Chenevix-Trench G, Australian Cancer Study, Australian Ovarian Cancer Study Group, Lu Y, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Despierre E, Vergote I, Lambrechts S, Doherty JA, Rossing MA, Chang-Claude J, Rudolph A, Friel G, Moysich KB, Odunsi K, Sucheston-Campbell L, Lurie G, Goodman MT, Carney ME, Thompson PJ, Runnebaum IB, Dürst M, Hillemanns P, Dörk T, Antonenkova N, Bogdanova N, Leminen A, Nevanlinna H, Pelttari LM, Butzow R, Bunker CH, Modugno F, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Karlan BY, Walsh C, Lester J, Jensen A, Kjær SK, Høgdall CK, Høgdall E, Lundvall L, Sellers TA, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Giles GG, Baglietto L, Severi G, Southey MC, Liang D, Wu X, Lu K, Hildebrandt MA, Levine DA, Bisogna M, Schildkraut JM, Iversen ES, Weber RP, Berchuck A, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Chandran U, Orlow I, Olson SH, Wik E, Salvesen HB, Bjorge L, Halle MK, van Altena AM, Aben KK, Kiemeney LA, Massuger LF, Pejovic T, Bean YT, Cybulski C, Gronwald J, Lubinski J, Wentzensen N, Brinton LA, Lissowska J, Garcia-Closas M, Dicks E, Dennis J, Easton DF, Song H, Tyrer JP, Pharoah PD, Eccles D, Campbell IG, Whittemore AS, McGuire V, Sieh W, Rothstein JH, Flanagan JM, Paul J, Brown R, Phelan CM, Risch HA, McLaughlin JR, Narod SA, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Gayther SA, Ramus SJ, Wu AH, Pearce CL, Pike MC, Dansonka-Mieszkowska A, Rzepecka IK, Szafron LM, Kupryjanczyk J, Cook LS, Le ND, Brooks-Wilson A, Ovarian Cancer Association Consortium. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet 133(5):481-97, 5/2014. e-Pub 11/2013. PMID: 24190013.
4. Tan W, Gu J, Huang M, Wu X, Hildebrandt MA. Epigenetic analysis of microRNA genes in tumors from surgically resected lung cancer patients and association with survival. Mol Carcinog. e-Pub 3/2014. PMID: 24665010.
5. Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, Rider DN, Sellers TA, Tworoger SS, Poole E, Risch HA, Salvesen HB, Kiemeney LA, Baglietto L, Giles GG, Severi G, Trabert B, Wentzensen N, Chenevix-Trench G, for AOCS/ACS group, Whittemore AS, Sieh W, Chang-Claude J, Bandera EV, Orlow I, Terry K, Goodman MT, Thompson PJ, Cook LS, Rossing MA, Ness RB, Narod SA, Kupryjanczyk J, Lu K, Butzow R, Dörk T, Pejovic T, Campbell I, Le ND, Bunker CH, Bogdanova N, Runnebaum IB, Eccles D, Paul J, Wu AH, Gayther SA, Hogdall E, Heitz F, Kaye SB, Karlan BY, Anton-Culver H, Gronwald J, Hogdall CK, Lambrechts D, Fasching PA, Menon U, Schildkraut J, Pearce CL, Levine DA, Kjaer SK, Cramer D, Flanagan JM, Phelan CM, Brown R, Massuger LF, Song H, Doherty JA, Krakstad C, Liang D, Odunsi K, Berchuck A, Jensen A, Lubinski J, Nevanlinna H, Bean YT, Lurie G, Ziogas A, Walsh C, Despierre E, Brinton L, Hein A, Rudolph A, Dansonka-Mieszkowska A, Olson SH, Harter P, Tyrer J, Vitonis AF, Brooks-Wilson A, Aben KK, Pike MC, Ramus SJ, Wik E, Cybulski C, Lin J, Sucheston L, Edwards R, McGuire V, Lester J, du Bois A, Lundvall L, Wang-Gohrke S, Szafron LM, Lambrechts S, Yang H, Beckmann MW, Pelttari LM, Van Altena AM, van den Berg D, Halle MK, Gentry-Maharaj A, Schwaab I, Chandran U, Menkiszak J, Ekici AB, Wilkens LR, Leminen A, Modugno F, Friel G, Rothstein JH, Vergote I, Garcia-Closas M, Hildebrandt MA, Sobiczewski P, Kelemen LE, Pharoah PD, Moysich K, Knutson KL, Cunningham JM, Fridley BL, Goode EL. Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with IL1A and TNFSF10. Cancer Res 74(3):852-61, 2/2014. e-Pub 11/2013. PMCID: PMC3946482.
6. Meng QH, Xu E, Hildebrandt MA, Liang D, Lu K, Ye Y, Wagar EA, Wu X. Genetic Variants in the Fibroblast Growth Factor Pathway as Potential Markers of Ovarian Cancer Risk, Therapeutic Response, and Clinical Outcome. Clin Chem 60(1):222-32, 1/2014. e-Pub 10/2013. PMID: 24146310.
7. Wang Y, Gu J, Roth JA,Hildebrandt MA, Lippman SM, Ye Y, Minna JD, Wu X. Pathway-based serum microRNA profiling and survival in patients with advanced non-small cell lung cancer. Cancer Res 73(15):4801-9, 8/2013. e-Pub 6/2013. PMCID: PMC3760306.
8. Wu X, Wang L, Ye Y, Aakre JA, Pu X, Chang GC, Yang PC, Roth JA, Marks RS, Lippman SM, Chang JY, Lu C, Deschamps C, Su WC, Wang WC, Huang MS, Chang DW, Li Y, Pankratz VS, Minna JD, Hong WK, Hildebrandt MA (co-last author), Hsiung CA, Yang P. Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers. Cancer Res 73(13):4028-4038, 7/2013. e-Pub 5/2013. PMCID: PMC3719971.
9. Schumacher FR, Wang Z, Skotheim RI, Koster R, Chung CC, Hildebrandt MA (co-first author), Kratz CP, Bakken AC, Bishop DT, Cook MB, Erickson RL, Fosså SD, Greene MH, Jacobs KB, Kanetsky PA, Kolonel LN, Loud JT, Korde LA, Le Marchand L, Lewinger JP, Lothe RA, Pike MC, Rahman N, Rubertone MV, Schwartz SM, Siegmund KD, Skinner EC, Turnbull C, Van Den Berg DJ, Wu X, Yeager M, Nathanson KL, Chanock SJ, Cortessis VK, McGlynn KA. Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. Hum Mol Genet 22(13):2748-53, 7/2013. e-Pub 3/2013. PMCID: PMC3674801.
10. Chung CC, Kanetsky PA, Wang Z, Hildebrandt MA (co-first author), Koster R, Skotheim RI, Kratz CP, Turnbull C, Cortessis VK, Bakken AC, Bishop DT, Cook MB, Erickson RL, Fosså SD, Jacobs KB, Korde LA, Kraggerud SM, Lothe RA, Loud JT, Rahman N, Skinner EC, Thomas DC, Wu X, Yeager M, Schumacher FR, Greene MH, Schwartz SM, McGlynn KA, Chanock SJ, Nathanson KL. Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet 45(6):680-5, 6/2013. e-Pub 5/2013. PMCID: PMC3723930.
11. Ke HL, Chen M, Ye Y, Hildebrandt MA, Wu WJ, Wei H, Huang M, Chang DW, Dinney CP, Wu X. Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer. Carcinogenesis 34(5):1006-11, 5/2013. e-Pub 1/2013. PMCID: PMC3643413.
12. Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila) 6(3):196-205, 3/2013. PMCID: PMC3608471.
13. Pu X, Roth JA, Hildebrandt MA, Ye Y, Wei H, Minna JD, Lippman SM, Wu X. MicroRNA-Related Genetic Variants Associated with Clinical Outcomes in Early Stage Non-Small Cell Lung Cancer Patients. Cancer Res 73(6):1867-75, 3/2013. e-Pub 2/2013. PMCID: PMC3602350.
14. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Köbel M, PRACTICAL Consortium, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Woo YL, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Weber RP, Vitonis AF, Vincent D, Vierkant RA, Vergote I, Van Den Berg D, Van Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen HB, Rzepecka IK, Runnebaum IB, Rossing MA, Rodriguez-Rodriguez L, Risch HA, Renner SP, Poole EM, Pike MC, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlow I, Omar SZ, Olson SH, Odunsi K, Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin JR, McGuire V, Matsuo K, Adenan NA, Massuger LF, Lurie G, Lundvall L, Lubinski J, Lissowska J, Levine DA, Leminen A, Lee AW, Le ND, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny GE, Kjaer SK, Kiemeney LA, Kelemen LE, Keeney GL, Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji BT, Jensen A, Jakubowska A, Iversen E, Hosono S, Høgdall CK, Høgdall E, Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle MK, Hall P, Gronwald J, Gore M, Goodman MT, Giles GG, Gentry-Maharaj A, Garcia-Closas M, Flanagan JM, Fasching PA, Ekici AB, Edwards R, Eccles D, Easton DF, Dürst M, du Bois A, Dörk T, Doherty JA, Despierre E, Dansonka-Mieszkowska A, Cybulski C, Cramer DW, Cook LS, Chen X, Charbonneau B, Chang-Claude J, Campbell I, Butzow R, Bunker CH, Brueggmann D, Brown R, Brooks-Wilson A, Brinton LA, Bogdanova N, Block MS, Benjamin E, Beesley J, Beckmann MW, Bandera EV, Baglietto L, Bacot F, Armasu SM, Antonenkova N, Anton-Culver H, Aben KK, Liang D, Wu X, Lu K, Hildebrandt MA, Australian Ovarian Cancer Study Group,Australian Cancer Study,Schildkraut JM,Sellers TA,Huntsman D,Berchuck A, Chenevix-Trench G, Gayther SA, Pharoah PD, Laird PW, G. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun 4:1628, 2013. PMID: 23535649.
15. Pu X, Ye Y, Spitz MR, Wang L, Gu J, Lippman SM, Hildebrandt MA, Hong WK, Minna JD, Roth JA, Yang P, Wu X. Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study. Clin Cancer Res 18(21):5983-91, 11/2012. e-Pub 9/2012. PMCID: PMC3640870.
16. Kim JY, Hildebrandt MA (co-first author), Pu X, Ye Y, Correa AM, Vaporciyan AA, Wu X, Roth JA. Variations in the Vascular Endothelial Growth Factor Pathway Predict Pulmonary Complications. Ann Thorac Surg 94(4):1079-85, 10/2012. e-Pub 7/2012. PMCID: PMC3466075.
17. Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, Huang M, Calin GA, Wang D, Dubois RN, Hawk ET, Wu X. Genetic polymorphisms in microRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res 18(14):3982-91, 7/2012. e-Pub 6/2012. PMID: 22661538.
18. Hildebrandt MA, Lippman SM, Etzel CJ, Kim E, Lee JJ, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X. Genetic variants in the PI3K/PTEN/AKT/MTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res 18(13):3705-13, 7/2012. e-Pub 5/2012. PMCID: PMC3404728.
19. Hildebrandt MA (corresponding author), Tan W, Tamboli P, Huang M, Ye Y, Lin J, Lee JS, Wood CG, Wu X. Kinome expression profiling identifies IKBKE as a predictor of overall survival in clear cell renal cell carcinoma patients. Carcinogenesis 33(4):799-803, 4/2012. e-Pub 1/2012. PMCID: PMC3324439.
20. Wei H, Ke HL, Lin J, Shete S, Wood CG, Hildebrandt MA. MicroRNA target site polymorphisms in the VHL-HIF1α pathway predict renal cell carcinoma risk. Mol Carcinog. e-Pub 4/2012. PMCID: PMC3424388.
21. Wu X, Scelo G, Purdue MP, Rothman N, Johansson M, Ye Y, Wang Z, Zelenika D, Moore LE, Wood CG, Prokhortchouk E, Gaborieau V, Jacobs KB, Chow WH, Toro JR, Zaridze D, Lin J, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Jinga V, Bencko V, Slamova A, Holcatova I, Navratilova M, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL, Boeing H, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, Duell EJ, Quirós JR, Sanchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Ljungberg B, Overvad K, Tjønneland A, Romieu I, Riboli E, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Virtamo J, Vatten L, Hveem K, Fletcher T, Koppova K, Cussenot O, Cancel-Tassin G, Benhamou S, Hildebrandt MA, Pu X, Foglio M, Lechner D, Hutchinson A, Yeager M, Fraumeni JF, Lathrop M, Skryabin KG, McKay JD, Gu J, Brennan P, Chanock SJ. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet 21(2):456-62, 1/2012. e-Pub 10/2011. PMCID: PMC3276284.
22. Xing J, Dinney CP, Shete S, Huang M, Hildebrandt MA, Chen Z, Gu J. Comprehensive pathway-based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer. Cancer 118(1):205-15, 1/2012. e-Pub 6/2011. PMCID: PMC3178723.
23. Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLoS One 7(5):e37891, 2012. e-Pub 5/2012. PMCID: PMC3360659.
24. Yin J, Lu C, Gu J, Lippman SM, Hildebrandt MA, Lin J, Stewart D, Spitz MR, Wu X. Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer. Carcinogenesis 32(12):1867-71, 12/2011. e-Pub 9/2011. PMCID: PMC3220611.
25. Tan W, Hildebrandt MA, Pu X, Huang M, Lin J, Matin SF, Tamboli P, Wood CG, Wu X. Role of inflammatory-related gene expression in clear cell renal cell carcinoma development and clinical outcomes. J Urol 186(5):2071-7, 11/2011. e-Pub 9/2011. PMCID: PMC3348612.
26. Lin M, Stewart DJ, Spitz MR, Hildebrandt MA, Lu C, Lin J, Gu J, Huang M, Lippman SM, Wu X. Genetic variations in the transforming growth factor beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis 32(7):1050-6, 7/2011. e-Pub 4/2011. PMCID: PMC3128559.
27. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 103(10):817-25, 5/2011. e-Pub 4/2011. PMCID: PMC3096796.
28. Gu J, Ye Y, Spitz MR, Lin J, Kiemeney LA, Xing J, Hildebrandt MA, Hong WK, Amos CI, Wu X. A genetic variant near the PMAIP1/Noxa gene is associated with increased bleomycin sensitivity. Hum Mol Genet 20(4):820-6, 2/2011. e-Pub 11/2010. PMCID: PMC3024041.
29. Lee JJ, Wu X, Hildebrandt MA (second author), Yang H, Khuri FR, Kim E, Gu J, Ye Y, Lotan R, Spitz MR, Hong WK. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 4(2):185-93, 2/2011. PMID: 21292633.
30. Pu X, Hildebrandt MA (co-first author), Lu C, Lin J, Stewart DJ, Ye Y, Gu J, Spitz MR, Wu X. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer 71(1):82-8, 1/2011. e-Pub 5/2010. PMCID: PMC2952281.
31. Yin J, Lu K, Lin J, Wu L, Hildebrandt MA, Chang DW, Meyer L, Wu X, Liang D. Genetic Variants in TGF-ß Pathway Are Associated with Ovarian Cancer Risk. PLoS One 6(9):e25559, 2011. e-Pub 9/2011. PMCID: PMC3184159.
32. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeney LA, Vineis P, De Vivo I, Albanes D, Purdue MP, Rafnar T, Hildebrandt MA (co-second author), Kiltie AE, Cussenot O, Golka K, Kumar R, Taylor JA, Mayordomo JI, Jacobs KB, Kogevinas M, Hutchinson A, Wang Z, Fu YP, Prokunina-Olsson L, Burdett L, Yeager M, Wheeler W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Grubb R, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Cortessis VK, Gago-Dominguez M, Pike MC, Stern MC, Yuan JM, Hunter DJ, McGrath M, Dinney CP, Czerniak B, Chen M, Yang H, Vermeulen SH, Aben KK, Witjes JA, Makkinje RR, Sulem P, Besenbacher S, Stefansson K, Riboli E, Brennan P, Panico S, Navarro C, Allen NE, Bueno-de-Mesquita HB, Trichopoulos D, Caporaso N, Landi MT, Canzian F, Ljungberg B, Tjonneland A, Clavel-Chapelon F, Bishop DT, Teo MT, Knowles MA, Guarrera S, Polidoro S, Ricceri F, Sacerdote C, Allione A, Cancel-Tassin G, Selinski S, Hengstler JG, Dietrich H, Fletcher T, Rudnai P, Gurzau E, Koppova K, Bolick SC, Godfrey A, Xu Z, Sanz-Velez JI, D García-Prats M, Sanchez M, Valdivia G, Porru S, Benhamou S, Hoover RN, Fraumeni JF, Silverman DT, Chanock SJ. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 42(11):978-84, 11/2010. e-Pub 10/2010. PMCID: PMC3049891.
33. Chen M, Hildebrandt MA (co-first author), Clague J, Kamat AM, Picornell A, Chang J, Zhang X, Izzo J, Yang H, Lin J, Gu J, Chanock S, Kogevinas M, Rothman N, Silverman DT, Garcia-Closas M, Grossman HB, Dinney CP, Malats N, Wu X. Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non-Muscle-Invasive Bladder Cancer. Cancer Prev Res (Phila) 3(10):1235-45, 10/2010. e-Pub 9/2010. PMCID: PMC2955764.
34. Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P, Wood CG, Wu X. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 29(42):5724-8, 10/2010. e-Pub 8/2010. PMID: 20676129.
35. Chen M, Gu J, Delclos GL, Killary AM, Fan Z, Hildebrandt MA, Chamberlain RM, Grossman HB, Dinney CP, Wu X. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis 31(8):1387-91, 8/2010. e-Pub 6/2010. PMCID: PMC2915631.
36. Clague J, Lippman SM, Yang H, Hildebrandt MA, Ye Y, Lee JJ, Wu X. Genetic variation in MicroRNA genes and risk of oral premalignant lesions. Mol Carcinog 49(2):183-9, 2/2010. PMCID: PMC3640857.
37. Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, Lippman SM, Cox JD, Hong WK, Spitz MR, Wu X. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One 5(8):e12402, 2010. e-Pub 8/2010. PMCID: PMC2928273.
38. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 27(6):857-71, 2/2009. e-Pub 1/2009. PMCID: PMC2738430.
39. Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, Yang H, Hildebrandt MA, Lin J, Ye Y, Chamberlain RM, Dinney CP, Wu X. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 30(12):2047-52, 2009. PMCID: PMC2792319.
40. Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, Hildebrandt M, Ames M, Schaid D, Wang L. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 68(17):7050-8, 9/2008. PMCID: PMC2562356.
41. Yu Z, Wang L, Hildebrandt MA, Schaid DJ. Testing whether genetic variation explains correlation of quantitative measures of gene expression, and application to genetic network analysis. Stat Med 27(19):3847-67, 8/2008. PMCID: PMC2729096.
42. Ji Y, Olson J, Zhang J, Hildebrandt M, Wang L, Ingle J, Fredericksen Z, Sellers T, Miller W, Dixon JM, Brauch H, Eichelbaum M, Justenhoven C, Hamann U, Ko Y, Brüning T, Chang-Claude J, Wang-Gohrke S, Schaid D, Weinshilboum R. Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res 68(14):5997-6005, 7/2008. PMCID: PMC2518124.
43. Moyer AM, Salavaggione OE, Wu TY, Moon I, Eckloff BW, Hildebrandt MA, Schaid DJ, Wieben ED, Weinshilboum RM. Glutathione s-transferase p1: gene sequence variation and functional genomic studies. Cancer Res 68(12):4791-801, 6/2008. PMCID: PMC2490824.
44. Wang L, Kumar S, Fridley BL, Kalari KR, Moon I, Pelleymounter LL, Hildebrandt MA, Batzler A, Eckloff BW, Wieben ED, Greipp PR. Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. Clin Cancer Res 14(11):3503-13, 6/2008. PMCID: PMC2778274.
45. Moyer AM, Salavaggione OE, Hebbring SJ, Moon I, Hildebrandt MA, Eckloff BW, Schaid DJ, Wieben ED, Weinshilboum RM. Glutathione S-transferase T1 and M1: gene sequence variation and functional genomics. Clin Cancer Res 13(23):7207-16, 12/2007. PMID: 18056202.
46. Hildebrandt MA, Carrington DP, Thomae BA, Eckloff BW, Schaid DJ, Yee VC, Weinshilboum RM, Wieben ED. Genetic diversity and function in the human cytosolic sulfotransferases. Pharmacogenomics J 7(2):133-43, 4/2007. e-Pub 6/2006. PMID: 16801938.
47. Schaid DJ, Batzler AJ, Jenkins GD, Hildebrandt MA. Exact tests of Hardy-Weinberg equilibrium and homogeneity of disequilibrium across strata. Am J Hum Genet 79(6):1071-80, 12/2006. e-Pub 11/2006. PMCID: PMC1698709.
48. Hildebrandt MA, Salavaggione OE, Martin YN, Flynn HC, Jalal S, Wieben ED, Weinshilboum RM. Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies. Biochem Biophys Res Commun 321(4):870-8, 9/2004. PMID: 15358107.
49. Thomae BA, Rifki OF, Theobald MA, Eckloff BW, Wieben ED, Weinshilboum RM. Human catecholamine sulfotransferase (SULT1A3) pharmacogenetics: functional genetic polymorphism. J Neurochem 87(4):809-19, 11/2003. PMID: 14622112.
50. Iverson ES, Weber RP, Concannon PJ, Marks JR, Berchuck A, Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer), Chenevix-Trench G, Hein A, Ekici AB, Beckman MW, Fasching PA, Lambrechts D, Despierre E, Vergote I, Lambrechts S, Doherty JA, Rossing MA, Chang-Claude J, Seibold P, Rudolph A, Friel G, Moysich KB, Odunsi K, Sucheston L, Lurie G, Goodman MT, Carney ME, Thompson PJ, Runnebaum I, Duerst M, Hillemanns P, Doerk T, Antonenkova N, Bogdanova N, Leminen A, Nevanlinna H, Pelttari LM, Butzow R, Bunker C, Modugno F, Edwards RP, Ness RB, Bois A, Heitz F, Schwabb I, Harter P, Karlan BY, Walsh C, Lester J, Jensen A, Kjaer SK, Hogdall E, Sellers TA, Fridley BL, Goode EL, Cunningham JM, Veirkant RA, Giles GG, Baglietto L, Severi G, Southey MC, Liang D, Lin J, Lu K, Hildebrandt MA, Levine DA, Bisogna M, Vitonis AF, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlow I, Olson SH, Chandran U, Wik E, Salvesen HB, Bjorge L, Halle MK, van Altena AM, Aben KKH, Kiemeney LA, Massuger LFAG, Hays LE, Pejovic T, Bean Y, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Gronwald K, Lubinski J, Jakibowska A, Krzystolik K, Wentzensen N, Brinton LA, Lissowska J, Garcia-Closas M, Baker H, Dicks E, Song H, Tyrer J, Pharoah PP, Eccles D, Campbell IG, Whittemore AS, McGuire V, Sieh W, Rothstein JH, Phelan CM, Risch HA, McLaughlin JR, Narod SA, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Gayther SA, Ramus SJ, Menon U, Harrington P, Wu AH, Pearce CL, Pike MC, Lee A, Budzilowska A, Plisiecka-Halasa J, Moes-Sosnowska J, Kupryjanczyk J, Schildkraut JM. Follow-Up of DNA Damage Response and Repair Gene Associations with Epithelial Ovarian Cancer - Evidence that Common Variation in CHEK2 Plays an Etiologic Role. Submitted.
51. Pierzynski JA, Hildebrandt MA, Kamat A, Lin J, Dinney CP, Wu X. Genetic Variants within the Wnt/β-catenin Signaling Pathway as Indicators of Bladder Cancer Risk And Clinical Outcomes. Submitted.
52. Hildebrandt MA, Roth JA, Vaporciyan AA, Pu X, Ye Y, Correa AM, Kim JY, Swisher SG, Wu X. Genetic variation in the TNF/TRAF2/ASK1/p38 kinase signaling pathway as markers for postoperative pulmonary complications in lung cancer patients. Submitted.

Invited Articles

1. Wu X, Hildebrandt MA, Chang DW. Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metastasis Rev 28(3-4):269-80, 12/2009. PMID: 20016998.
2. Hildebrandt MA, Ajani JA, Hofstetter W, Swisher S, Wu X. The role of PI3K/PTEN/AKT/mTOR Genetic Variation and Clinical Outcomes following Chemoradiotherapy for Esophageal Cancer. Am J Hemtol Oncol, 9/2009.
3. Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol 5(7):745-55, 7/2009. PMID: 19442035.
4. Hildebrandt M, Adjei A, Weinshilboum R, Johnson JA, Berlin DS, Klein TE, Altman RB. Very important pharmacogene summary: sulfotransferase 1A1. Pharmacogenet Genomics 19(6):404-6, 6/2009. PMID: 19451861.

Grant & Contract Support

Title: Post-GWA studies in TGCT
Funding Source: NIH/NCI
Role: Principal Investigator - MDACC (Subcontract)
Principal Investigator: Kate Nathanson (University of Pennsylvania)
Duration: 9/21/2012 - 8/31/2016
 
Title: Molecular pathways linking obesity and RCC tumorigenesis: PQ1
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Xifeng Wu
Duration: 9/1/2012 - 6/30/2016

Last updated: 7/22/2014